Tower Research Capital LLC (Trc) Fate Therapeutics Inc Transaction History
Tower Research Capital LLC (Trc)
- $3.68 Billion
- Q3 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 6,885 shares of FATE stock, worth $9,157. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,885
Previous 22,117
68.87%
Holding current value
$9,157
Previous $72,000
66.67%
% of portfolio
0.0%
Previous 0.0%
Shares
27 transactions
Others Institutions Holding FATE
# of Institutions
178Shares Held
113MCall Options Held
53.7KPut Options Held
9K-
Redmile Group, LLC San Francisco, CA13.2MShares$17.5 Million3.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.4MShares$13.8 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$13.5 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.57MShares$7.41 Million0.72% of portfolio
-
State Street Corp Boston, MA5.25MShares$6.99 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $129M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...